Jupiter Topco LLC Acquires New Position in Collegium Pharmaceutical, Inc. $COLL

Jupiter Topco LLC acquired a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,147,072 shares of the specialty pharmaceutical company’s stock, valued at approximately $77,743,000. Jupiter Topco LLC owned approximately 0.07% of Collegium Pharmaceutical at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in COLL. Group One Trading LLC acquired a new position in shares of Collegium Pharmaceutical during the 4th quarter worth $28,000. Caitong International Asset Management Co. Ltd boosted its stake in Collegium Pharmaceutical by 205.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 427 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new stake in Collegium Pharmaceutical in the fourth quarter valued at about $61,000. PNC Financial Services Group Inc. grew its position in Collegium Pharmaceutical by 42.2% in the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 418 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in Collegium Pharmaceutical by 744.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after acquiring an additional 2,190 shares during the last quarter.

Collegium Pharmaceutical Price Performance

Shares of COLL opened at $26.44 on Friday. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32. The stock has a market cap of $860.89 million, a PE ratio of 21.32 and a beta of 0.73. Collegium Pharmaceutical, Inc. has a 12-month low of $25.47 and a 12-month high of $50.79. The business has a 50-day simple moving average of $33.12 and a two-hundred day simple moving average of $35.13.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $199.88 million for the quarter, compared to analyst estimates of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The business’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period last year, the firm posted $1.68 earnings per share. Analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on COLL. Needham & Company LLC dropped their target price on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Zacks Research cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Barclays dropped their price objective on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating for the company in a research note on Wednesday, August 19th. Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Finally, Weiss Ratings lowered shares of Collegium Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $51.00.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.